Robert W. Baird reissued their buy rating on shares of Tenet Healthcare (NYSE:THC) in a research report released on Wednesday morning. Robert W. Baird currently has a $35.00 target price on the stock.

THC has been the topic of a number of other reports. ValuEngine raised shares of Tenet Healthcare from a sell rating to a hold rating in a research note on Thursday, November 1st. Barclays reaffirmed a hold rating and issued a $27.00 price objective on shares of Tenet Healthcare in a research note on Wednesday. Piper Jaffray Companies reiterated a hold rating and issued a $34.00 target price on shares of Tenet Healthcare in a report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Tenet Healthcare from a hold rating to a buy rating and set a $36.00 target price for the company in a report on Wednesday, August 8th. Finally, Mizuho set a $36.00 target price on shares of Tenet Healthcare and gave the company a buy rating in a report on Tuesday, August 7th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $30.56.

Tenet Healthcare stock opened at $26.29 on Wednesday. Tenet Healthcare has a 1-year low of $12.45 and a 1-year high of $39.74. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 32.46, a price-to-earnings-growth ratio of 1.23 and a beta of 0.87. The company has a debt-to-equity ratio of 21.55, a quick ratio of 1.01 and a current ratio of 1.06.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Monday, November 5th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.18. Tenet Healthcare had a negative net margin of 0.61% and a positive return on equity of 47.38%. The firm had revenue of $4.49 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the firm earned ($0.17) earnings per share. The business’s quarterly revenue was down 2.1% compared to the same quarter last year. Equities research analysts predict that Tenet Healthcare will post 1.63 EPS for the current year.

Several hedge funds have recently made changes to their positions in THC. Advisors Preferred LLC purchased a new stake in shares of Tenet Healthcare in the second quarter valued at about $163,000. NumerixS Investment Technologies Inc purchased a new stake in Tenet Healthcare during the second quarter worth about $166,000. Assetmark Inc. increased its holdings in Tenet Healthcare by 45.8% during the second quarter. Assetmark Inc. now owns 5,093 shares of the company’s stock worth $171,000 after buying an additional 1,601 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Tenet Healthcare by 286.0% during the first quarter. Cubist Systematic Strategies LLC now owns 7,700 shares of the company’s stock worth $187,000 after buying an additional 5,705 shares during the last quarter. Finally, Vident Investment Advisory LLC purchased a new stake in Tenet Healthcare during the second quarter worth about $207,000.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company. It operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. The company's general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

Read More: Balance Sheet

Analyst Recommendations for Tenet Healthcare (NYSE:THC)

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.